2024-511684-28-00RecruitingPhase 2
Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Mar 2026
Brief summary (registry, in English)
Long-term safety
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 13 Mar 2024
- Start date
- 1 Sept 2025
- Lead sponsor
- Autolus Limited
- Diseases
- Childhood cancers
- EU CT number
- 2024-511684-28-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 21
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- There are no exclusion criteria for this study.
Who the study is looking for
- Patients must have received an AUTO CAR T cell therapy on a previous treatment study.
- Patients must have provided informed consent for long-term follow-up study prior to participation.
- Patients must be able to comply with the study requirements.
Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Infantil Universitario Nino Jesus Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hospital Universitario Y Politecnico La Fe Coordinator of this site? Confirm its status | Valencia | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.